The US Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) to Siemens Healthineers’ semi-quantitative SARS-CoV-2 IgG antibody test COV2G.

COV2G is the first antibody test to secure authorisation with a semi-quantitative detection claim. It provides more than 99% sensitivity and specificity.

The test delivers a positive or negative result for IgG antibodies in the form of a numerical result expressed as an index value.

A positive or negative result for IgG antibodies provides information regarding an individual’s previous exposure to SARS-CoV-2 virus.

Siemens said that the test also obtained the European CE-mark and is available globally.

Siemens Healthineers Laboratory Diagnostics president Deepak Nath said: “Our high-quality antibody test helps clinicians assess the level of a person’s immune response, which is an important tool to have at this stage of the pandemic.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“Siemens Healthineers offers a robust portfolio of reliable tests to help support patient care and fight Covid-19.”

The company added that a semi-quantitative result helps clinicians to analyse the IgG antibodies levels in a patient’s blood sample. Clinicians can use this numerical value to determine a baseline and track the changes in the immune response to the virus.

Also, numerical results can be compared to investigate the development of SARS-CoV-2 antibodies over time in an individual.

The company’s SARS-CoV-2 Total antibody test identifies IgM and IgG antibodies present early and later during the immune response, while the COV2G test detects IgG antibodies that persist and aid long-term immune response.

Siemens expects the combination of these tests to offer complete insights into a patient’s serological status.

The COV2G antibody test can be used on analysers in the US and CE-Mark accepting countries, including the Atellica Solution and ADVIA Centaur XP and XPT analysers.